Discover the top 25 companies transforming the global cell therapy technologies market, including Danaher Corporation, Merck KGaA, Thermo Fisher Scientific Inc., and other industry leaders. Backed by a market projected to grow from $4.41B to $7.91B by 2030 at a CAGR of 12.4%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.

Download PDF Brochure:“Click Here”

Spotlights on the Industry’s Top Cell Therapy Technologies Companies

Danaher Corporation

Danaher Corporation is a global science and technology innovator committed to helping customers solve complex challenges and improving quality of life around the world. In the cell therapy technologies market, Danaher operates primarily through its Cytiva and Pall Corporation brands, providing end-to-end solutions for cell processing, fluid management, and manufacturing scale-up. The company’s portfolio includes advanced bioreactors, cell culture media, and automated platforms designed to streamline the production of CAR-T and other advanced cellular therapies.

Merck KGaA

Merck KGaA is a leading science and technology company that provides a comprehensive range of products and services for the biopharmaceutical industry. Through its Life Science business, the company offers integrated solutions for cell therapy development, including specialized media, reagents, and sterile filtration technologies. Merck focuses on accelerating the path from research to commercialization by providing scalable manufacturing platforms and regulatory expertise to ensure the safety and efficacy of next-generation cell-based medicines.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is a world leader in serving science, offering an extensive array of technologies and services to support the cell therapy lifecycle. The company provides specialized cell culture systems, gene editing tools like CRISPR, and automated cell processing equipment under brands such as Gibco and Invitrogen. Thermo Fisher’s commitment to innovation is evidenced by its investments in manufacturing capacity and its ability to provide integrated workflows that enhance productivity and standardization across the cell therapy industry.

Lonza

Lonza is a prominent global contract development and manufacturing organization (CDMO) that specializes in providing integrated solutions for the cell and gene therapy markets. The company’s proprietary Cocoon Platform offers an automated, closed system for patient-scale cell therapy manufacturing, significantly reducing the risks of contamination and human error. Lonza’s expertise spans from early-stage process development to commercial-scale production, making it a critical partner for biotech companies seeking to bring transformative cellular treatments to patients.

Sartorius AG

Sartorius AG is a leading international partner for life science research and the biopharmaceutical industry, focusing on innovative technologies that improve the efficiency of drug development. In the cell therapy space, Sartorius provides a robust portfolio of single-use bioreactors, cell culture media, and advanced analytical tools for process monitoring. The company’s solutions are designed to support the transition from manual to automated processes, ensuring high-quality cell production while maintaining strict regulatory compliance.

Agilent Technologies, Inc.

Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, providing laboratories worldwide with instruments, services, and expertise. For the cell therapy sector, Agilent offers specialized analytical tools such as the Seahorse XF analyzers and xCELLigence real-time cell analysis systems to monitor cell potency, fitness, and metabolic profiles. These technologies enable researchers to characterize engineered immune cells with high precision, supporting the development of more effective and reliable cellular therapeutics.

Avantor, Inc.

Avantor, Inc. is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, and technology industries. The company supports cell therapy workflows by providing high-purity chemicals, specialized excipients, and customized single-use assemblies essential for sterile manufacturing. Avantor’s global distribution network and technical expertise help cell therapy developers maintain supply chain integrity and achieve consistent production outcomes at both clinical and commercial scales.

Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA is a global healthcare group that provides products and services for dialysis, hospitals, and outpatient medical care. Through its Fresenius Kabi division, the company is expanding its presence in the cell therapy market by offering specialized medical devices and solutions for cell processing and infusion. Fresenius focuses on enhancing patient safety and treatment accessibility by leveraging its extensive clinical network and expertise in handling complex biological products.

Becton, Dickinson and Company

Becton, Dickinson and Company (BD) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD Biosciences provides critical tools for cell therapy research and manufacturing, including advanced flow cytometry systems like the BD FACSLyric and single-cell multiomics platforms. These technologies allow for deep characterization and quality control of cellular products, ensuring that therapeutic cells meet specific phenotype and potency standards.

Corning Incorporated

Corning Incorporated is a world leader in materials science, providing innovative glass and ceramic solutions for life sciences and other high-tech industries. The company offers a variety of specialized cell culture vessels and surfaces, such as the HYPERStack and CellSTACK platforms, which are designed to maximize cell yield in a compact footprint. Corning’s technologies support the scalable production of adherent cells, providing critical infrastructure for the expansion of stem cells and other therapeutic cell types.

Terumo Corporation

Terumo Corporation is a global medical technology leader based in Japan, providing a wide range of solutions for cardiovascular care and blood management. Its Terumo Blood and Cell Technologies division is a key player in the cell therapy market, offering automated systems like the Quantum Cell Expansion System and the Finia Fill and Finish System. These platforms focus on automating critical steps in the cell manufacturing process, from expansion to final packaging, to improve consistency and reduce manual intervention.

Bio-Techne

Bio-Techne is a leading developer and manufacturer of high-quality purified proteins and specialized reagents for the life science industry. The company provides essential components for cell therapy manufacturing, including GMP-grade cytokines, growth factors, and small molecules for cell differentiation and expansion. Bio-Techne’s focus on quality and consistency ensures that researchers and manufacturers have the reliable raw materials necessary to produce potent and standardized cellular therapies.

GenScript

GenScript is a leading biology group that provides a wide range of services and products for life science research and drug discovery. In the cell therapy market, the company offers specialized tools for gene editing and cell engineering, including custom CRISPR reagents and viral vector manufacturing services. GenScript’s expertise in synthetic biology supports the development of next-generation CAR-T and TCR-T therapies by providing researchers with high-precision engineering solutions.

MaxCyte

MaxCyte is a leading provider of cell-engineering platform technologies focused on advancing the next generation of cell-based medicines. The company’s Flow Electroporation technology allows for the highly efficient and low-toxicity delivery of genetic material into a wide variety of cell types. MaxCyte’s scalable platforms are used by biopharmaceutical companies to engineer therapeutic cells with high precision, supporting the development of clinical-stage therapies for cancer and rare diseases.

STEMCELL Technologies

STEMCELL Technologies is a global biotechnology company that develops specialty cell culture media, separation products, and accessory reagents for life science research. The company provides standardized tools for the isolation and expansion of various cell types, including hematopoietic stem cells and immune cells used in therapy development. STEMCELL’s commitment to “Scientists Helping Scientists” drives its focus on providing high-quality, reliable products that enhance reproducibility in cell therapy research.

Oxford Biomedica plc

Oxford Biomedica plc is a leading gene and cell therapy group focused on the development and manufacturing of lentiviral vector-based therapies. The company’s LentiVector platform is a key technology used for the genetic modification of cells in many leading cell therapy programs. Oxford Biomedica provides end-to-end development and manufacturing services to global pharmaceutical partners, leveraging its deep expertise in viral vector engineering to ensure high-titer and high-quality production.

RoosterBio, Inc.

RoosterBio, Inc. is a privately held biotechnology company focused on accelerating the development of a sustainable regenerative medicine industry. The company provides standardized, high-volume mesenchymal stem/stromal cell (MSC) working cell banks and highly engineered media systems. RoosterBio’s products are designed to simplify the manufacturing of MSC-based therapies, reducing time and costs for researchers and enabling the rapid scale-up of cellular products for clinical use.

TrakCel

TrakCel is a leading software developer providing advanced supply chain management solutions for the cell and gene therapy industry. Its Ocellos platform offers a cellular orchestration system that tracks the complex journey of a patient’s cells from collection through manufacturing to final infusion. TrakCel’s technology ensures chain of identity and chain of custody, providing the transparency and compliance necessary to manage the logistical challenges of personalized medicine.

L7 Informatics, Inc.

L7 Informatics, Inc. provides unified data management and automation solutions for the life sciences industry through its L7|ESP platform. In the cell therapy market, L7’s technology helps manufacturers integrate disparate data sources, automate complex workflows, and maintain regulatory compliance across the product lifecycle. By providing a “digital backbone” for cell therapy manufacturing, L7 enables companies to improve operational efficiency and ensure the highest quality standards for their products.

Miltenyi Biotec

Miltenyi Biotec is a global leader in providing products and services for biomedical research and cellular therapy. The company’s CliniMACS Prodigy is a widely used, automated system that integrates all stages of cell manufacturing, from cell separation and washing to expansion and formulation. Miltenyi Biotec’s comprehensive portfolio supports a wide range of applications, including the production of CAR-T cells and the processing of stem cells for regenerative medicine.

Repligen Corporation

Repligen Corporation is a bioprocessing technology leader focused on products that enhance the efficiency and quality of biological drug manufacturing. In the cell therapy technologies market, Repligen provides innovative fluid management, filtration, and monitoring solutions that are integrated into automated manufacturing workflows. The company’s commitment to process intensification helps cell therapy manufacturers optimize yields and reduce production cycles through advanced components and systems.

MAK SYSTEM

MAK SYSTEM is a leading provider of medical software specialized in blood management and cellular therapy. The company’s software solutions manage the entire process of cell collection, processing, and distribution, ensuring full traceability and compliance with international quality standards. MAK SYSTEM’s technology supports the complex logistics of cell therapy by providing integrated tools for donor management, inventory tracking, and clinical follow-up.

OriGen Biomedical, Inc.

OriGen Biomedical, Inc. is a leading manufacturer of medical devices for use in cell culture, cryopreservation, and respiratory care. The company provides specialized bags and containers designed for the storage and freezing of therapeutic cells, such as the CryoStore line. OriGen’s products are recognized for their durability and biocompatibility, ensuring the safe and reliable handling of sensitive biological materials throughout the cell therapy manufacturing and delivery process.

iXCells Biotechnologies

iXCells Biotechnologies is a cell biology-based research organization that provides high-quality primary cells, iPSC-derived cells, and related media products. The company supports cell therapy discovery by offering a diverse range of human cell models and specialized services for drug screening and disease modeling. iXCells’ expertise in cell engineering and characterization helps researchers identify promising therapeutic candidates and optimize cell-based assays for clinical development.

Körber AG

Körber AG is an international technology group that provides integrated solutions for the pharmaceutical and biotech industries. Through its Pharma business area, the company offers specialized packaging, inspection, and software solutions for the cell therapy market, including advanced Manufacturing Execution Systems (MES). Körber’s technology focuses on digitalizing the production process and ensuring full transparency and compliance, helping cell therapy manufacturers scale their operations efficiently.

Download PDF Brochure:“Click Here”